Compare BlackRock TCP Capital Corp (TCPC) vs Tango Therapeutics Inc. (TNGX) Price & Performance

TCPC trades at $3.98 with no recent price movement. The stock shows a bullish technical signal with strong moving average support, though oscillators remain neutral. Fundamentally, the company reported negative revenue and net income for 2025, with declining trends projected into 2026. Recent positive developments include Q2 2026 earnings beats and a $523 million portfolio sale that reduced leverage. Analyst sentiment is mixed with 30.77% buy ratings but 69.23% hold recommendations.

TCPC presents a complex investment case with attractive valuation metrics including P/B of 0.62 suggesting potential undervaluation, but significant fundamental challenges with negative revenue and profitability trends. The strategic portfolio sale and ongoing business review offer potential catalysts, though investors face risks from the class action lawsuit and persistent negative cash flow. The dividend yield remains a positive factor for income-focused investors.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.